Fig. 6

Comparison of fenretinide levels in blood and tumours of mice treated with standard NCI-FeR or Bio-nFeR formulations. a Fenretinide concentration (± standard deviation) in plasma (expressed in ng/ml and the corresponding μM concentration are indicated) and tumours (in ng/g and the extrapolated μM concentration assuming tumour density as approximately = 1) of mice after 3 weeks 100 mg/kg oral administration of each drug formulation. b Fenretinide metabolites levels in plasma and tumours of the same samples as in A. Fenretinide, 4HPR, OXO-4HPR and DH-4HPR concentration levels in the indicated plasma and tumours of the same samples as in A